<DOC>
	<DOCNO>NCT01386398</DOCNO>
	<brief_summary>RATIONALE : Vorinostat bortezomib may stop growth tumor cell block enzymes need cell growth . It yet know whether vorinostat effective give alone give together bortezomib treat patient refractory recurrent cutaneous T-cell lymphoma . PURPOSE : This randomized phase III trial study well vorinostat work give alone compare vorinostat give together bortezomib treat patient refractory recurrent stage IIB , stage III , stage IV cutaneous T-cell lymphoma .</brief_summary>
	<brief_title>Vorinostat With Without Bortezomib Treating Patients With Refractory Recurrent Stage IIB , Stage III , Stage IV Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine combination bortezomib plus vorinostat ( SAHA ) effective vorinostat alone , term prolong progression-free survival , patient stage IIB-IV cutaneous T-cell lymphoma fail prior therapy . Secondary - To determine overall survival patient . - To determine response rate patient . - To determine time progression patient . - To determine duration response patient . - To determine incidence second cancer patient . - To determine acute late toxicity regimen patient . - To determine translational research may provide insight disease mechanism identify biomarkers useful prediction treatment response . ( Exploratory ) OUTLINE : This multicenter study . Patients stratify accord type cutaneous T-cell lymphoma ( mycosis fungoides vs erythrodermic mycosis fungoides/Sézary syndrome ) , number prior chemotherapy regimen ( 1 v ≥ 2 ) , country . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral vorinostat ( SAHA ) daily absence disease progression unacceptable toxicity . - Arm II : Patients receive bortezomib IV day 1 , 4 , 8 , 11 oral vorinostat daily day 1-14 . Treatment repeat every 21 day progression unacceptable toxicity . Blood tissue sample collect periodically translational research provide insight disease mechanism identify biomarkers useful prediction treatment response . After completion study treatment , patient follow 4 week every 3 month disease progression .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced cutaneous Tcell lymphoma ( CTCL ) , include variant mycosis fungoides Sézary syndrome Stage IIBIV disease Relapsed refractory disease , include follow : Patients clinical progression follow EORTC21081 protocol treatment Intolerant ≥ 1 prior intravenous chemotherapy , include denileukin diftitox , antibody antibody conjugate , systemic therapy No CNS involvement PATIENT CHARACTERISTICS : WHO performance status 02 Absolute neutrophil count &gt; 1.5 x 10^9/L* Platelet count &gt; 100 x 10^9/L* Hemoglobin &gt; 9 g/dL* WBC &gt; 3 x 10^9/L* Bilirubin ≤ 1.5 time upper limit normal ( ULN ) * AST ALT ≤ 3 time ULN ( case liver infiltration ≤ 5 x ULN ) * Serum creatinine ≤ 2.0 mg/dL* Calculated creatinine clearance ≥ 60 mL/min Electrolytes ( include potassium magnesium ) ≤ 1 time ULN* Not pregnant nursing prior first dose study treatment 4 week last study treatment Negative pregnancy test Fertile patient must use effective contraception 3 month completion study therapy Able swallow capsule able take tolerate oral medication continuous basis No New York Heart Association class IIIIV disease None follow know condition : Infectious disease Autoimmune disease Immunodeficiency No known active HIV and/or hepatitis A , B , C infection No NCI CTC grade 1 peripheral sensory neuropathy pain peripheral sensory motor neuropathy ≥ grade II No malignancy within past 5 year No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule NOTE : *Patients buffer range normal value +/ 5 % hematology +/ 10 % biochemistry acceptable , except renal function . PRIOR CONCURRENT THERAPY : See Disease Characteristics Must completely recover previous treatment toxicity No prior splenectomy splenic irradiation No prior bortezomib and/or histone deacetylase inhibitor ( include vorinostat [ SAHA ] ) More 4 week since prior chemotherapy , immunotherapy , radiotherapy , surgery In case clear progression previous treatment , 2 week washout enough No concurrent chemotherapy , immunotherapy , radiotherapy , surgery ( except biopsy ) No concurrent steroid ( prednisone equivalent ) dose &gt; 20 mg/day Prednisone ≤ 20 mg/day treatment disorder CTCL allow No concomitant use histone deacetylase inhibitor ( e.g. , valproic acid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>